GlassScriptPhysician profile
Katherine Carter
NPI 1730601006
$5,446.95
in general payments reported to CMS, 2019-2025
45 companies · $22.96 in 2025
The $22.96 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,158 · 2023: $4,022 · 2024: $245 · 2025: $22.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,276 · Education: $13.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,275.73 |
| Education | $13.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,215.53 | 2022-2024 | |
| Neurelis, INC. | $374.63 | 2023 | Valtoco |
| Genentech USA, INC. | $264.34 | 2022-2023 | Ocrevus |
| Neurocrine Biosciences, INC. | $190.18 | 2022-2023 | Ingrezza, Ongentys |
| Celgene Corporation | $183.86 | 2022-2023 | Zeposia |
| Ani Pharmaceuticals, INC. | $174.05 | 2022-2023 | Purified Cortrophin Gel |
| Csl Behring | $164.67 | 2023 | Hizentra |
| Lilly USA, LLC | $125.97 | 2022-2023 | Emgality, Amyvid |
| Pfizer INC. | $125.13 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.34 | 2022-2023 | |
| Ucb, INC. | $108.03 | 2022-2023 | Fintepla |
| Teva Pharmaceuticals USA, INC. | $89.10 | 2023 | Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $88.46 | 2022-2023 | Quviviq |
| Emd Serono, INC. | $83.19 | 2023 | Mavenclad |
| Xeris Pharmaceuticals, INC. | $78.85 | 2023-2024 | Keveyis, Gvoke Hypopen |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.